Clinical Trials Browser

NIH × Paclitaxel × Breast × Clear all

NCT05673200 2026-03-18

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT06058377 2026-03-18

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Phase 3 Recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3 Active not recruiting

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast Neoplasms

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01275677 2025-07-14

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Phase 3 Completed

3,270 enrolled 16 charts

Breast Neoplasms

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT02474173 2022-11-04

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00785291 2022-10-10

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Phase 3 Completed

799 enrolled 18 charts

Breast Neoplasms

NCT00470301 2021-02-16

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1/2 Completed

60 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00005970 2020-08-14

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT01688609 2017-09-11

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

Phase 2 Completed

18 enrolled 7 charts

Breast Neoplasms

NCT01263145 2017-08-25

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01276496 2016-03-15

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00368875 2015-11-05

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Phase 1/2 Completed

54 enrolled 9 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01238133 2015-09-04

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00535119 2015-05-22

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase 1 Completed

BreastGynecologic

Hereditary Breast and Ovarian Cancer Syndrome

NCT00301730 2015-04-28

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00054028 2015-03-17

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

Phase 1/2 Completed

31 enrolled 16 charts

Breast Neoplasms

NCT00119262 2014-05-15

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Phase 2 Completed

226 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00002627 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00002628 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT00003253 2013-12-19

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms, Breast Neoplasms, Male

NCT00005581 2013-12-18

Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00003013 2013-09-17

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00533936 2013-08-26

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00070278 2013-08-07

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00002662 2013-08-02

Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00311636 2013-06-26

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Phase 3 Completed

Breast Neoplasms

NCT00052351 2013-06-19

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00003440 2013-06-04

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

Phase 3 Completed

Breast Neoplasms

NCT00028535 2013-06-04

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

Phase 1 Completed

BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00003992 2013-06-03

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

Phase 2 Completed

Breast Neoplasms

NCT00048893 2012-04-13

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Phase 1/2 Terminated

37 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00019812 2012-03-23

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00019019 2012-03-15

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Phase 1 Completed

BreastCNSDermatologicGenitourinaryGynecologicLymphoidOther hematologic neoplasmSarcomaThoracic

Carcinoma, Ovarian Epithelial, Astrocytoma, Brain Neoplasms, Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Craniopharyngioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Meningioma, Mycosis Fungoides, Oligodendroglioma, Ovarian Neoplasms, Pinealoma, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Neuroectodermal Tumors, Primitive, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT00006120 2008-07-24

Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00001383 2008-03-04

A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

Phase 1 Completed

BreastGenitourinaryGynecologicLymphoid

Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, Neoplasms, Ovarian Neoplasms

NCT00001498 2008-03-04

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

Phase 2 Completed

Breast Neoplasms